NOVEMBER 7–9, 2018
New York Marriott Marquis
New York, NY

PROGRAM CO-CHAIRS:

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA

Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, D.C.

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY

BENEFITS IN ATTENDING THIS YEAR’S CFS®!

• Network with the top minds in oncology
• Incorporate the latest clinical data into your practice
• Challenge the experts with your most difficult cases
• 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting.

For more information and registration, visit us at gotoper.com/go/CFS18BRO
OVERVIEW

Each year, the Chemotherapy Foundation Symposium® (CFS®), brings together more than 1,000 healthcare professionals for 3 days, with one goal in mind: promoting evidence-based science into state-of-the-art cancer care.

At this year’s 36th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics.

Join us in November for Innovative Cancer Therapy for Tomorrow®!

ANNOUNCING THE KEYNOTE SPEAKER: TIKI BARBER

Best known for his time on the field, former New York Giants football player Tiki Barber serves as co-host of CBS Sports Radio’s “Tiki & Tierney”. Barber is one of three NFL players in football history with more than 10,000 career rushing yards and 5,000 career yards receiving.

Tiki was 22 and playing for the University of Virginia Cavaliers when his mother was diagnosed with breast cancer. Initially keeping her diagnosis a secret, Tiki’s mother fought through several forms of therapy and came out on top. She’s now been in remission for two decades. Today Tiki tells her motivational story to raise awareness and help others through the same journey his family endured.

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>ADVANCED</th>
<th>ON-SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$599</td>
<td>$699</td>
</tr>
<tr>
<td>Fellows*</td>
<td>$249</td>
<td>$349</td>
</tr>
<tr>
<td>Nurses, PAs, Other Healthcare Professionals</td>
<td>$249</td>
<td>$349</td>
</tr>
<tr>
<td>Industry**</td>
<td>$749</td>
<td>$849</td>
</tr>
</tbody>
</table>

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

TWO WAYS TO REGISTER

Online

gotoper.com /go/CFS18BRO

or

Call

1-609-378-3701

For any other question email us at: info@gotoper.com
# AGENDA

**Wednesday, November 7, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 AM</td>
<td>Breakfast (Exhibit Hall)</td>
</tr>
<tr>
<td>6:55 AM</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td></td>
<td><strong>Hematology</strong></td>
</tr>
<tr>
<td>7:00 AM</td>
<td>Evaluating the Integration of JAK Inhibition Strategies for the Management of PV</td>
</tr>
<tr>
<td>7:15 AM</td>
<td>Second-Line Therapy After JAK Inhibition in MF</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>What Should You Do If Azacitidine Is No Longer Working for Your Patient With MDS?</td>
</tr>
<tr>
<td></td>
<td><strong>Chronic Lymphocytic Leukemia</strong></td>
</tr>
<tr>
<td>7:45 AM</td>
<td>CLL: Novel Agents, Novel Combinations</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Medical Crossfire®: Chemotherapy Versus Novel Agents in Modern Management of CLL</td>
</tr>
<tr>
<td></td>
<td><strong>Lymphoma</strong></td>
</tr>
<tr>
<td>8:20 AM</td>
<td>Breaking the Ceiling of R-CHOP in DLBCL</td>
</tr>
<tr>
<td>8:35 AM</td>
<td>Checkpoint Immunotherapy in Lymphoma: Present and Future</td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Assessment of Evolving Targeted Strategies in Follicular Lymphoma</td>
</tr>
<tr>
<td></td>
<td><strong>Leukemias</strong></td>
</tr>
<tr>
<td>9:05 AM</td>
<td>Novel Immune-Based Therapies for AML</td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Targeted Therapies for AML</td>
</tr>
<tr>
<td>9:35 AM</td>
<td>Optimizing Outcomes in ALL: Assessment of State-of-the-Art Strategies and Proactive Toxicity Management</td>
</tr>
<tr>
<td>9:50 AM</td>
<td>Key Sequencing Considerations in CML Treatment</td>
</tr>
<tr>
<td></td>
<td><strong>CAR-T Focus</strong></td>
</tr>
<tr>
<td>10:05 AM</td>
<td>Assessing Pivotal Data Sets With the Use of CAR T Therapies</td>
</tr>
<tr>
<td>10:20 AM</td>
<td>Practical Applications and Considerations for CAR T: Optimizing Use in the Clinic</td>
</tr>
<tr>
<td></td>
<td><strong>Multiple Myeloma</strong></td>
</tr>
<tr>
<td>11:10 AM</td>
<td>Frontline Therapy for Multiple Myeloma in 2018</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>Current Role of Minimal Residual Disease Testing in Multiple Myeloma</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>Novel Therapies in Relapsed/Refractory Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td><strong>Rare Hematologic Malignancies</strong></td>
</tr>
<tr>
<td>11:55 AM</td>
<td>Key Considerations: When and How to Treat Patients With Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Novel Targeted Therapies in a Rare Cancer</td>
</tr>
<tr>
<td>12:25 PM</td>
<td>Non-CME Lunch Symposia - lunch provided</td>
</tr>
<tr>
<td></td>
<td><strong>Sarcoma</strong></td>
</tr>
<tr>
<td>1:40 PM</td>
<td>Key Concepts in the Diagnosis and Treatment of Soft-Tissue Sarcomas</td>
</tr>
<tr>
<td></td>
<td><strong>Genitourinary Cancers</strong></td>
</tr>
<tr>
<td>3:25 PM</td>
<td>Oligometastatic Disease: Novel Imaging and the Role of Local Therapy</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Immunotherapy and Targeted Agents in Prostate Cancer</td>
</tr>
<tr>
<td>3:55 PM</td>
<td>Immunotherapy in Bladder Cancer</td>
</tr>
<tr>
<td>4:10 PM</td>
<td>What to Do After Checkpoint Inhibitor Failure: Emerging Agents and Combinations</td>
</tr>
<tr>
<td>4:25 PM</td>
<td>Medical Crossfire®: Targeted Therapy, Immunotherapy, and Chemotherapy for Advanced Bladder Cancer: What is the Right Treatment? What is the Right Sequence?</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>GU Panel and Audience Q&amp;A</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Adjourn</td>
</tr>
<tr>
<td>5:00 - 6:00 PM</td>
<td>Welcome Reception (Exhibit Hall)</td>
</tr>
<tr>
<td>6:30 AM - 8:00 AM</td>
<td>Concurrent CME Symposium – Bring Your Own Case (BYOC™)! Addressing Challenging Clinical Scenarios in Breast Cancer</td>
</tr>
</tbody>
</table>
## Nursing Track - Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>Welcome</td>
<td></td>
</tr>
<tr>
<td>5:05 PM</td>
<td>Pathology 101: Reading and Understanding the Pathology Report</td>
<td>Ann Culkin, RN, OCN®</td>
</tr>
<tr>
<td>5:25 PM</td>
<td>Clinical Pearls in Managing Immune-Mediated Toxicities</td>
<td>Massey Nematollahi, RN, MScN, OCN®, CONC</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>Latest Practices in Lymphedema</td>
<td>Julie Pederson, BSW, RN, OCN®, CBCN</td>
</tr>
<tr>
<td>6:05 PM</td>
<td>Hematology: Integrating New Therapies Into Practice</td>
<td>Beth Faiman, PhD, CNP</td>
</tr>
<tr>
<td>6:25 PM</td>
<td>Q&amp;A</td>
<td>Panel</td>
</tr>
<tr>
<td>6:35 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>6:55 PM</td>
<td>The Importance of Tobacco Control in Oncology: A Nursing Perspective</td>
<td>Linda Sarna, PhD, RN, FAAN</td>
</tr>
<tr>
<td>7:15 PM</td>
<td>Navigating Patients Through Cancer</td>
<td>Kathleen A. Gamblin, RN, BSN, OCN</td>
</tr>
<tr>
<td>7:35 PM</td>
<td>The Latest and Greatest in Breast Cancer</td>
<td>Adam M. Brufsky, MD, PhD</td>
</tr>
<tr>
<td>7:55 PM</td>
<td>Sexuality After Cancer: The Nurse’s Role</td>
<td>Anne Katz, PhD, RN, FAAN</td>
</tr>
<tr>
<td>8:15 PM</td>
<td>Panel and Audience Q&amp;A</td>
<td>Panel</td>
</tr>
</tbody>
</table>

## Thursday, November 8, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 AM</td>
<td>Breakfast (Exhibit Hall)</td>
<td></td>
</tr>
<tr>
<td>6:55 AM</td>
<td>Welcome</td>
<td>Moderator: Susana M. Campos, MD, MPH</td>
</tr>
<tr>
<td>7:00 AM</td>
<td>PARP Inhibitors: Combinatorial Therapy</td>
<td>Susana M. Campos, MD, MPH</td>
</tr>
<tr>
<td>7:15 AM</td>
<td>The Role of Immunotherapy in Gynecologic Cancer</td>
<td>Patrick Ott, MD, PhD</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Novel Therapies and Roles for Current Agents in Ovarian Cancer (non-PARP, non-IO)</td>
<td>Bradley J. Monk, MD, FACS, FACOG</td>
</tr>
<tr>
<td>7:45 AM</td>
<td>Advances in the Management of Cervical Cancer</td>
<td>Gini Fleming, MD</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Gynecologic Cancers: The Impact of BRCA (Dys) Function on Biology and Treatment</td>
<td>Franco M. Muggia, MD</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>Medical Crossfire®: Chemotherapy Improves Outcomes In Patients With Early-Stage, High-Risk Uterine Cancer</td>
<td>Moderator: Susana M. Campos, MD, MPH, Angeles A. Secord, MD, Maurie Markman, MD, Gini Fleming, MD, Franco M. Muggia, MD</td>
</tr>
<tr>
<td>8:35 AM</td>
<td>Current Sequences and Future Triples in Melanoma</td>
<td>Geoffrey T. Gibney, MD</td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Up-to-Date Adjuvant Therapy in Melanoma</td>
<td>Hussein Tawbi, MD, PhD</td>
</tr>
<tr>
<td>9:00 AM - 10:30 AM</td>
<td>Concurrent CME Symposium – Medical Crossfire®: An Oncologist’s Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment</td>
<td></td>
</tr>
<tr>
<td>9:05 AM</td>
<td>Clinical Trial Updates in the Treatment of Advanced Cutaneous Squamous-Cell Carcinoma</td>
<td>Moderator: Jason J. Luke, MD, FACP, Anna C. Pavlick, BSN, MS, DO, MBA, tofu, C. Pavlick, BS, MS, DO, MBA, Richard D. Carvajal, MD, Hussein Tawbi, MD, PhD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>The Intersection Between Genomics and Immunotherapy</td>
<td>Nadeem Riaz, MD, MSc</td>
</tr>
<tr>
<td>9:55 AM</td>
<td>Immune Checkpoint Blockade-Based Combination Therapies</td>
<td>Jason J. Luke, MD, FACP</td>
</tr>
<tr>
<td>10:10 AM</td>
<td>Biomarkers for Immunotherapy</td>
<td>Kurt A. Schalper, MD, PhD</td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Optimizing Outcomes Through Improved Immunotherapy-Related Adverse Event Management</td>
<td>Richard D. Carvajal, MD</td>
</tr>
<tr>
<td>10:40 AM</td>
<td>Break (Exhibit Hall)</td>
<td></td>
</tr>
</tbody>
</table>

## Keynote Lectures

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 AM</td>
<td>Giants of Cancer Care Lecture: Viewing Ovarian Cancer As A Chronic Illness: An Increasing Need For Both Therapeutic ‘Precision’ And A Focus On Quality-of-Life</td>
<td>Maurie Markman, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Greenspan Lecture: What’s in Your Basket? The Promise and Clinical Questions Surrounding Histology-Agnostic Trials</td>
<td>David Hyman, MD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Celebrity Keynote Presentation Introduction</td>
<td>Phil Talamo, CHCP</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Celebrity Keynote Presentation and Q&amp;A</td>
<td>Tiki Barber</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>Non-CME Lunch Symposia - lunch provided</td>
<td></td>
</tr>
</tbody>
</table>

## Breast Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 PM</td>
<td>Molecularly Guided Management of Breast Cancer</td>
<td>Joseph A. Sparano, MD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Putting PARP Inhibitors Into Practice in Breast Cancer</td>
<td>Mark E. Robson, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Management of HER2+ Disease: Optimal Regimens, Optimal Durations</td>
<td>Chau T. Dang, MD</td>
</tr>
<tr>
<td>2:00 PM - 3:30 PM</td>
<td>Concurrent CME Symposium – Medical Crossfire®: Evaluating Immuno-Oncology Strategies Across Tumor Types</td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>State-of-the-Art Neoadjuvant Approaches in Breast Cancer</td>
<td>Adam M. Brufsky, MD, PhD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Break (Exhibit Hall)</td>
<td></td>
</tr>
</tbody>
</table>
**Adjuvant Therapy for ER+ Breast Cancer**

Ruth O’Regan, MD

**Medical Crossfire®: LHRH Preserves Fertility in Premenopausal Women With Early Breast Cancer**

Moderator: Adam Brufksy, MD, PhD
PRO: Matteo Lambertini, MD
CON: Kutluk Oktay, MD, PhD

**Assisted Reproductive Technology for Women Seeking Fertility Preservation**

Kutluk Oktay, MD, PhD

**CDK4/6 Inhibitors: A Practice Update**

Joyce A. O'Shaughnessy, MD

**What’s New in Immunotherapy for Breast Cancer?**

Heather L. McArthur, MD, MPH

**Breast Panel and Audience Q&A**

Breast Cancer Faculty

**“How I Do It” Track - Thursday**

5:00 PM  Welcome
5:05 PM  How I Use Bone-Modifying Agents in the Metastatic Setting
Catherine Van Poznak, MD, FASCO
5:35 PM  How I Manage Immunotherapy-Related Adverse Events
Bryan J. Schneider, MD
6:05 PM  How I Treat Locally Advanced Rectal Cancer
Christopher Liu, MD
6:35 PM  Break
6:55 PM  How Do I Select First-Line Therapy in RCC?
Che-Kai Tsao, MD
7:25 PM  How I Treat Totally Advanced Rectal Cancer
Adil I. Daud, MD
7:55 PM  How I Choose Between Single-Agent Anti-PD-1 Therapy or Anti-PD-1/CTLA4 Combination Therapy
Peter Martin, MD
8:25 PM  How I Treat Early Relapsing Follicular Lymphoma

**Friday, November 9, 2018**

6:00 AM  Breakfast (Exhibit Hall)
6:55 AM  Welcome

**Lung Cancers**

7:00 AM  The Treatment-Naive Patient Without an Actionable Mutation: Navigating the New Regimens
Hossein Borghaei, MS, DO
7:15 AM  Optimal Management for Patients With Advanced Squamous NSCLC
Mark A. Socinski, MD
7:30 AM  Novel Immunotherapy Combination Strategies in NSCLC
Roy S. Herbst, MD, PhD
7:45 AM  Leading to Cure: Incorporating Immunotherapy and Targeted Therapy in Earlier-Stage Disease
Balazs Halmos, MD
8:00 AM  Multimodality Therapy
Shirish M. Gadgeel, MD
8:15 AM  ALK-Directed Therapies: How Should We Sequence?
D. Ross Camidge, MD, PhD
8:30 AM  EGFR-Mutated Lung Cancer: Frontline Strategies and Beyond
Sarah B. Goldberg, MD, MPH
8:45 AM  The More, the Merrier: Expanding Array of Oncogenic Drivers (including BRAF, MET, NTRK, RET, and ROS1)
Alexander E. Drilon, MD
9:00 AM  Plasma Genotyping in NSCLC: How to Use Liquid Biopsies Along the NSCLC Treatment Continuum
Joshua Bauml, MD
9:15 AM  New Treatment Approaches for Small Cell Lung Cancer
Roman Perez-Soler, MD
9:30 AM  Antiangiogenesis in Lung Cancer: Can It Survive in the World of IO Therapy?
Mark G. Kris, MD
9:45 AM  Emerging Treatment Options for Mesothelioma and Thymoma
Stephen V. Liu, MD
10:00 AM  Medical Crossfire®: Which Biomarker Is Best to Guide Clinical Decision Making With IO Therapy? PD-L1, TMB, or Nothing at All?
Moderator: Benjamin Levy, MD
Mark A. Socinski, MD; Hossein Borghaei, MS, DO; Sarah B. Goldberg, MD, MPH; Roy S. Herbst, MD, PhD
10:20 AM  Break (Exhibit Hall)

**Gastrointestinal Cancers**

Moderator: Cathy Eng, MD, FACP
10:50 AM  Individualizing Therapy for Gastric Cancer
David H. Ilson, MD, PhD
11:05 AM  With Many Emerging Options, How Will We Sequence Therapies for Hepatocellular Carcinoma?
Anthony B. El-Khoueiry, MD
11:20 AM  New Multidisciplinary Treatment Opportunities in an Era of Expanding Treatment Options
Ghassan K. Abou-Alfa, MD, MBA
11:35 AM  Pancreas Cancer: Locally Advanced, Unresectable Pancreatic Cancer
Eileen M. O’Reilly, MD
11:50 AM  Key Sequencing Considerations in the Management of Advanced Colorectal Cancer
Jordan Berlin, MD
12:05 PM  Evolving Targeted and Immunotherapeutic Options for Colorectal Cancer
Cathy Eng, MD, FACP
12:20 PM  Evaluating Evolving Approaches and Combinations in the Management of Neuroendocrine Tumors
Diane Reidy Lugunes, MD
12:35 PM  Medical Crossfire®: The MSI Story in GI and Lessons Translated Pan-Tumor
Moderator: Cathy Eng, MD, FACP
Jordan Berlin, MD; Anthony B. El-Khoueiry, MD; David H. Ilson, MD, PhD; Eileen M. O’Reilly, MD
12:55 PM  Non-CME Lunch Symposia - lunch provided
Glioblastoma Multiforme

2:10 PM  Clinical Trial Update: Immunotherapy Strategies and Their Application in GBM
David A. Reardon, MD

2:25 PM  Key Evidence on the Use of Tumor-Treating Fields for GBM Management
Rimas V. Lukas, MD

2:40 PM  Targeted Therapies and Their Emerging Role in the Treatment of GBM
Andrew B. Lassman, MD

2:55 PM  Oncolytic Virus Therapies for GBM
Henry S. Friedman, MD

Head, Neck, Thyroid Cancers

3:10 PM  Recent Advances in the Management of Head and Neck Squamous Cell Carcinoma
Dan P. Zandberg, MD

3:25 PM  Immunotherapeutic and Targeted Approaches: Evolving Roles in the Management of Thyroid Cancer
Marcia S. Brose, MD, PhD

3:40 PM  BREAK

Patient-Centered Care and Oncology Practice
Moderator: Patrick I. Borgen, MD

4:05 PM  Key Concepts to Maximize the Prevention and Treatment of CINV
Richard J. Gralla, MD, FACP

4:20 PM  Addressing the Opioid Epidemic With Effective Postoperative Pain Management Strategies
Patrick I. Borgen, MD

4:35 PM  Novel Strategies to Manage Neutropenia and Optimize Outcomes in Cancer Care
Jeffrey Crawford, MD

4:50 PM  Oncology Practice, Research, and Patient Engagement in the Digital Health Age
Edward P. Ambinder, MD

5:05 PM  Closing Remarks

5:10 PM  Adjourn

Agenda subject to change.

COMMITTEE MEMBERS

Arjun V. Balar, MD
Perlmutter Cancer Center, NYU Langone
New York, NY

Susana M. Campos, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Ajai Chari, MD
The Mount Sinai Hospital
New York, NY

Alexander E. Drilon, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Cathy Eng, MD, FACP
The University of Texas MD Anderson Cancer Center
Houston, TX

Jason J. Luke, MD, FACP
The University of Chicago Medicine
Chicago, IL

John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
New York, NY

FACULTY

Ghassan K. Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY

Edward P. Ambinder, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Joshua Bauml, MD
University of Pennsylvania
Philadelphia, PA

Jordan Berlin, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Patrick J. Borgen, MD
Brooklyn Breast Cancer Program
Brooklyn, NY

Hossein Borghaei, MS, DO
Fox Chase Cancer Center
Philadelphia, PA

Joshua Brody, MD
Hess Center for Science and Medicine
New York, NY

Marcia Simpson Brose, MD, PhD
Hospital of the University of Pennsylvania
Philadelphia, PA

D. Ross Camidge, MD, PhD
University of Colorado Denver School of Medicine
Denver, CO

George P. Canellos, MD
Dana-Farber Cancer Institute
Boston, MA

Richard D. Carvajal, MD
Columbia University Medical Center
New York, NY

Toni K. Choueiri, MD
Harvard Medical School
Boston, MA

Jeffrey Crawford, MD
Duke Cancer Institute
Durham, NC

Ann Culkin, RN, QCN®
Memorial Sloan Kettering Cancer Center
Middletown, NJ

Chau T. Dang, MD
Memorial Sloan Kettering Cancer Center
West Harrison, NY

Adil I. Daud, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Naval G. Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Brian G.M. Durie, MD
Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA

Anthony B. El-Khoueiry, MD
University of Southern California
Los Angeles, CA

Beth Faiman, PhD, CNP
Cleveland Clinic
Cleveland, OH

Robert L. Ferris, MD, PhD
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Robert A. Figlin, MD, FACP
Cedars-Sinai Medical Center
Los Angeles, CA

Gini Fleming, MD
The University of Chicago Medicine
Chicago, IL

Richard R. Furman, MD
Weill Cornell Medical College
New York, NY

Shirish M. Gadgeel, MD
University of Michigan
Ann Arbor, MI

Matthew Galsky, MD
Icahn School of Medicine at Mount Sinai
New York, NY
FACULTY

A. Gamblin, RN, BSN, OCN
Varian Medical Systems
Atlanta, GA

Geoffrey T. Gibney, MD
George-Lombardi Comprehensive Cancer Center
Chevy Chase, MD

Sarah B. Goldberg, MD, MPH
Yale School of Medicine/Yale Cancer Center
New Haven, CT

Richard J. Gralla, MD, FACP
Albert Einstein College of Medicine
Bronx, NY

Petros Grivas, MD, PhD
University of Washington Medical Center
Seattle, WA

Balazs Halmos, MD
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Roy S. Herbst, MD, PhD
Yale Cancer Center, Smilow Cancer Hospital
New Haven, CT

Maha H. Hussain, MD, FACP, FASCO
Northwestern University Feinberg School of Medicine
Chicago, IL

David H. Ilson, MD, PhD
Weill Cornell Medical College
New York, NY

Gopakumar V. Iyer, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Anne Katz, PhD, RN, FAAN
CancerCare Manitoba
Winnipeg, Manitoba, Canada

Marina Kremjanskaia, MD, PhD
The Mount Sinai Hospital
New York, NY

Mark G. Kris, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Matteo Lambertini, MD
Institut Jules Bordet
Brussels, Belgium

C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

John P. Leonard, MD
Weill Cornell Medicine and New York-Presbyterian Hospital
New York, NY

Christopher Lieu, MD
University of Colorado Anschutz Medical Campus
Aurora, CO

Stephen V. Liu, MD
Georgetown University Medical Center
Washington, D.C.

Rimas V. Lukas, MD
Northwestern University
Chicago, IL

Ravi A. Madan, MD
National Cancer Institute
Bethesda, MD

Maurie Markman, MD
Drexel University College of Medicine
Philadelphia, PA

Peter Martin, MD
Weill Cornell Medicine
New York, NY

Michael J. Mauro, MD
Weill Cornell Medical College
New York, NY

Heather L. McArthur, MD, MPH
Cedars-Sinai Medical Center
Los Angeles, CA

Bradley J. Monk, MD, FACS, FACOG
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Franco M. Muggia, MD
NYU Langone Medical Center
New York, NY

Massey Nematollahi, RN, MScN, OCN®, CON®
Stronach Regional Cancer Center at Southlake Regional Health Center
Ontario, Canada

Eileen M. O’Reilly, MD
Weill Cornell Medical College
New York, NY

Kutluk Oktay, MD, PhD
Yale University School of Medicine
New Haven, CT

Joyce A. O’Shaughnessy, MD
The US Oncology Network
Dallas, TX

Patrick Ott, MD, PhD
Harvard Medical School
Boston, MA

Jae H. Park, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Anna C. Pavlick, BSN, MS, DO, MBA
NYU Medical Oncology Associates
New York, NY

Julie Pederson, BSW, RN, OCN, CBCN
Baylor Scott & White McClintock Cancer Center
Waco, TX

Naveen Pemmaraju, MD
MD Anderson Cancer Center
Houston, TX

Roman Perez-Soler, MD
Albert Einstein College of Medicine
Bronx, NY

Alexander Perl, MD
University of Pennsylvania
Philadelphia, PA

Azra Raza, MD
Columbia University Medical Center
New York, NY

Diane Reidy Lagunes, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Nadeem Riaz, MD, MSc
Memorial Sloan Kettering Cancer Center
New York, NY

Mark E. Robson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Linda Sarna, PhD, RN, FAAN
UCLA School of Nursing
Los Angeles, CA

Bryan J. Schneider, MD
University of Michigan
Ann Arbor, MI

Angeles Alvarez Secord, MD
Duke Cancer Institute
Durham, NC

Mark A. Socinski, MD
Florida Hospital Cancer Institute
Orlando, FL

Joseph A. Sparano, MD
Montefiore Medical Center
Bronx, NY

Hussein Tawbi, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Steven Treon, MD, PhD
Harvard Medical School
Boston, MA

Catherine Van Poznak, MD, FASCO
University of Michigan
Ann Arbor, MI

Srdan Verstovsek, MD, PhD
MD Anderson Cancer Center
Houston, TX

Andrew J. Wagner, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

David R. Wise, MD, PhD
NYU Langone Health
New York, NY

Anas Younes, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Michael J. Zelefsky, MD
Weill-Cornell Medical School
New York, NY

Faculty accurate at time of printing.
I COME TO CFS TO GATHER INFORMATIVE INFORMATION THAT WILL HELP ME PROVIDE GREAT PATIENT CARE.